United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

United States - English - NLM (National Library of Medicine)

carilion materials management - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - etidronate disodium (unii: m16pxg993g) (etidronate disodium - unii:m16pxg993g) - etidronate disodium 1 kg in 1 kg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - disodium etidronate 200mg - tablet - 200 mg - active: disodium etidronate 200mg excipient: magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - etidronate disodium, quantity: 400 mg - tablet, uncoated - excipient ingredients: maize starch; purified water; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - etidronate disodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - etidronate disodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - etidronate disodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - etidronate disodium -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - etidronate disodium - oral tablet - 200mg